Alnylam to Webcast Presentations at Upcoming September Investor Conferences
September 02 2020 - 8:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will present
company overviews at the following conferences being held
virtually:
- Citi 15th Annual BioPharma Virtual Conference on Thursday,
September 10, 2020 at 10:45 am ET
- Morgan Stanley 18th Annual Global Healthcare Conference on
Tuesday, September 15, 2020 at 9:30 am ET
- Cantor Virtual Global Healthcare Conference on Wednesday,
September 16, 2020 at 3:20 pm ET
- BofA Global Healthcare Conference on Thursday, September 17,
2020 at 2:10 pm BST (9:10 am ET)
A live audio webcast of each presentation will be available on
the Investors section of the Company’s website at
www.alnylam.com/events. A replay will be available on the Alnylam
website within 48 hours after each event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare genetic, cardio-metabolic, hepatic infectious, and central
nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically
validated approach for the treatment of a wide range of severe and
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust RNAi therapeutics platform. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO ® (patisiran), approved in the
U.S., EU, Canada, Japan, Switzerland and Brazil, and GIVLAARI ®
(givosiran), approved in the U.S. and EU. Alnylam has a deep
pipeline of investigational medicines, including six product
candidates that are in late-stage development. Alnylam is executing
on its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on Twitter at @Alnylam or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200902005098/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024